The global hypoparathyroidism treatment market is on a trajectory of significant expansion, according to a recent market analysis conducted by Future Market Insights. Valued at USD 777.4 million in 2022, the market is expected to reach approximately USD 841.9 million by the conclusion of 2023. The analysis further projects a steady Compound Annual Growth Rate (CAGR) of 7.7% from 2023 to 2033, with an anticipated market value of USD 1,767.4 million by the end of the forecast period.
Hypoparathyroidism, characterized by inadequate levels of parathyroid hormone, is a rare endocrine disorder driving the demand for advanced treatment options. This market expansion underscores a growing emphasis on developing innovative therapeutic interventions to meet the unmet medical needs of patients affected by this condition.
Get your Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-7857
“The anticipated growth of the hypoparathyroidism treatment market reflects a critical need for novel therapies tailored to address the challenges faced by patients,” remarked a Future Market Insights. “As healthcare providers and pharmaceutical companies intensify their efforts in research and development, we foresee a robust market landscape conducive to substantial advancements in treatment modalities.”
Key players in the hypoparathyroidism treatment market are poised to capitalize on emerging opportunities driven by technological advancements and increasing investment in healthcare infrastructure. The market analysis highlights a burgeoning interest in personalized medicine and biopharmaceutical innovations aimed at enhancing patient outcomes.
Key Takeaways:
- Over the next several decades, the Indian market is expected to grow at an 8.6% CAGR.
- By 2033, the worldwide market is expected to be worth USD 1767.4 million.
- The United States has emerged as the dominant market, accounting for more than 37.7% of overall demand in 2022.
- Over the next several decades, the Chinese market is expected to grow at a CAGR of 7.9%.
- In 2022, the calcium supplements category accounted for 38.29% of market revenue.
Competitive Landscape:
- Amolyt Pharma revealed an oral presentation at the 25th European Congress of Endocrinology (ECE) 2023 in May 2023. The presentation highlights the potential benefits of eneboparatide as a treatment for hypoparathyroidism, an illness in which numerous individuals have or are at risk of developing osteopenia and osteoporosis.
- In November 2022, the Food and Drug Administration (FDA) authorized for Priority Assessment a new drug application (NDA) for TransConTM PTH (palopegteriparatide) in adults with hypoparathyroidism.
Ignite Innovation with Customization: https://www.futuremarketinsights.com/customization-available/rep-gb-7857
Key Companies Profiled:
- Takeda Pharmaceutical Company Limited.
- Entera Bio Ltd.
- Amgen Inc.
- Ascendis Pharma A/S
- F. Hoffmann-La Roche Ltd
- ProLynx, Inc.
- Extend Biosciences, Inc.
- BionPharma Inc.
- Teva Pharmaceuticals Ltd.
Hypoparathyroidism Treatment Market Segmentation:
By Product Type:
- Parathyroid Hormone
- Natpara
- Others
- Vitamin D Analogue
- Vitamin D2
- Vitamin D3
- Calcium Supplements
By Route of Administration:
- Oral
- Parenteral
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Sales
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
Get Full Report: https://www.futuremarketinsights.com/checkout/7857
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
